Nearly missed this at the bottom of the page (last line). Not long to wait for another announcement!
Zelira has made other advances in using its proprietary products, most notably opioid reduction for people suffering chronic pain. It is currently involved in an Opioid Reduction Study in collaboration with St Vincent’s Hospital in Melbourne. It is undertaking a study to assess the safety and effectiveness of medical cannabis to reduce opioid dependence. Prescription opioids treating chronic pain are linked to serious side effects, which is a growing global crisis.
The Phase I pharmacokinetic trial is evaluating the safety and tolerability of whole plant extract following single and repeated doses in nine patients with chronic non-cancer pain on long-term opioid analgesia. Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the study. The trial is fully enrolled. No serious adverse events have been reported to date. The company is due to provide a final report of this study this month.
ZLD Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
